Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Sees Clouds Over Prograf, Irribow; Launches Vesicare In Asia To Drive Growth

This article was originally published in PharmAsia News

Executive Summary

Facing U.S. market expansion for generic Prograf (tacrolimus), a 14-year running blockbuster immunosuppressant, Japan's second-largest drug maker Astellas hopes to cultivate its next blockbuster from mirabegron, and ride the strong performance of Vesicare (solifenacin) to drive global growth by launching the drug in emerging Asian markets such as Singapore and China

You may also be interested in...



Astellas Pipeline Set For Patent Cliff Rebound

TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff

Astellas Pipeline Set For Patent Cliff Rebound

TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff

Astellas Sees Turnaround With Urology, Transplantation And Oncology Products

Astellas has rolled out a five-year management plan to bounce back from patent expiries and declining sales; and fresh off a long-fought bid for OSI Pharmaceuticals, the company expects oncology to bolster growth driven by its core therapeutic competencies of urology and transplantation

Related Content

UsernamePublicRestriction

Register

SC070515

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel